Reports Q4 revenue $58.4M, consensus $57.49M. “Our team successfully executed its goals in 2023 and launched PacBio on a trajectory this company has never seen before,” said Christian Henry, President and CEO of PacBio. “We continue to build solutions across the workflow, allowing our customers to further scale on HiFi, and we are encouraged to see how researchers are already making discoveries and shifting paradigms with the power and economics of Revio and the extraordinary accuracy of Onso.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on PACB:
- PACB Earnings this Week: How Will it Perform?
- Canaccord still bullish on 10x Genomics, PacBio despite reducing 2024 estimates
- Cathie Wood’s ARK Investment bought 908K shares of PacBio today
- Pac Bio call volume above normal and directionally bullish
- Cathie Wood’s ARK Investment bought 340K shares of PacBio today
